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Purpose: To evaluate the short-term anti-inflammatory effect of dexamethasone/netilmicin 
fixed combination in the management of ocular inflammation after cataract surgery.
Patients and Methods: Open-label, randomized, active-controlled, clinical study con-
ducted in 6 sites in Italy; 238 patients were randomized 2:1 to dexamethasone/netilmicin 
(dexa/net, n=158) or betamethasone/chloramphenicol (beta/chl, n=80). Treatment started 
the day of surgery and continued 4 times daily for 7 days. The primary efficacy parameter 
was the anterior chamber (AC) flare. The percentage of patients displaying none or mild (ie, 
only barely detectable) AC flare was defined as “efficacy rate”, whereas the percentage of 
patients showing a decrease of AC flare score from baseline was defined as “percentage of 
responders”. Additional parameters evaluated were AC cells, conjunctival hyperaemia, 
corneal and lid oedema, symptoms of ocular discomfort, visual acuity, and intraocular 
pressure. Dexa/net was considered effective if the efficacy rate was not inferior (by means 
of 97.5% confidence interval) to that of beta/chl.
Results: After 7 days of treatment, no AC flare was observed in 92.8% (dexa/net) and 92.3% 
(beta/chl) of patients, whereas no AC cells were observed in 91.5% (dexa/net) and 93.6% 
(beta/chl) of patients, respectively. The “efficacy rate” was 100% in both groups, whereas the 
“percentage of responders” was 94.1% in the dexa/net and 93.6% in the beta/chl group. The 
p-value to reject the null hypothesis of inferiority was <0.001. Other efficacy parameters 
confirmed both treatments as highly effective, despite their difference in steroid content 
(2 mg/mL for beta/chl vs 1 mg/mL for dexa/net). IOP and visual acuity at the end of the 
study were comparable. Two cases of allergic conjunctivitis were considered adverse events 
and were both related to dexa/net.
Conclusion: Short-term use of dexa/net fixed combination is safe and effective in the 
control of post-operative inflammation following uncomplicated cataract surgery.
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Introduction
Cataract surgery the most common surgical medical procedure performed annually 
across the European Union states in approximately 5 million individuals.1 After 
cataract extraction, a varying degree of post-surgical inflammation may occur. 
Although such inflammation is, in most cases, self-limited, the use of anti- 
inflammatory agents can rapidly resolve it and prevents serious complications 
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resulting from uncontrolled inflammations (as cystoid 
macular edema).2 Accordingly, the use of topical corticos-
teroids and/or non-steroidal anti-inflammatory drugs 
remains the mainstay of post-surgical management of 
these patients. A recent study funded by the European 
Society of Cataract and Refractive Surgeons (ESCRS) 
showed that a combination of a non-steroidal anti- 
inflammatory drugs and dexamethasone reduces the risk 
for developing cystoid macular oedema after cataract 
surgery.3 Apart ocular inflammation, endophthalmitis is 
the most important complication of cataract surgery. Its 
severity depends on the virulence and the quantity of 
inoculated pathogens. Coagulase-negative Staphylococci 
and S. Aureus are the most common pathogens isolated 
in this infection.4 Moreover, during the past decade 
a major concern was related to the high prevalence of 
infections due to methicillin-resistant S. Aureus (MRSA) 
and methicillin-resistant Coagulase-negative 
Staphylococci (MRCoNS). A preoperative antisepsis of 
the periocular area with topical povidone–iodine and the 
use of intracameral cefuroxime are actually considered the 
standard for endophthalmitis prophylaxis.5,6 However, 
cefuroxime is not effective versus methicillin-resistant 
strains.4 The use of post-operative topical antibiotics is 
controversial, but they are frequently used in the real life 
to sterilize the ocular surface and prevent any access of 
microorganisms inside the eye.6,7 Topical antibiotics can 
be administered either alone or in combination with corti-
costeroids. Steroid/antibiotic fixed combinations have sev-
eral advantages over the use of single components, as 
better compliance, lower costs, and reduction of the poten-
tial wash-out effect.8 The choice among different products 
depends on the bacterial susceptibility to the antibiotic and 
the type and strength of the steroid included in the for-
mulation. A steroid/antibiotic fixed combination contain-
ing 1 mg/mL dexamethasone and 3 mg/mL netilmicin is 
available in several EU and non-EU countries under the 
trade name of Netildex (SIFI SpA, Italy) and exhibits 
a fast and effective control of ocular inflammation, either 
post-operative or not.8–10 Since the use of dexamethasone 
after cataract surgery is established,11 the product’s added 
value is the presence of netilmicin, a wide spectrum anti-
biotic also covering methicillin-resistant strains ensuring 
a complete sterilization of the ocular surface in the 
immediate post-surgery period.12–14 In this study, a short 
treatment with such steroid-antibiotic combination was 




This was a multicenter, open, randomized, active- 
controlled, parallel group, Phase IV clinical study con-
ducted in 6 sites in Italy at Bari, Milano Verona, 
Catania, and Rome (2 centres). The main objective of 
the study was to evaluate the effectiveness of 1 mg/mL 
dexamethasone plus 3 mg/mL netilmicin (dexa/net) 
ophthalmic solution treatment for 7 days in the control 
and treatment of post-surgical ocular inflammation fol-
lowing cataract surgery. A control group of patients was 
treated with 2 mg/mL betamethasone plus 5 mg/mL 
chloramphenicol (beta/chl) eye suspension. The study 
protocol was approved by the institutional review 
board at each research center. All participants provided 
written informed consent and the study was conducted 
according to the Declaration of Helsinki and Good 
Clinical Practice guidelines. The trial is registered at 
the European Union Clinical Trials Register (EudraCT) 
no. 200600330513.
Participants
Any subject older than 40 years, able to give an informed 
consent and scheduled for having micro-incisional cataract 
surgery was eligible for the study. Subjects were considered 
not eligible if they had: 1) history of ocular inflammatory 
diseases, ocular herpes infection, iritis, uveitis or Sjogren’s 
syndrome, 2) concomitant ocular pathologies, 3) intraocular 
pressure >24 mmHg; 4) previous ocular surgery in the affected 
eye in the previous 12 months; 5) previous laser treatment in 
the affected eye in the previous 6 months; 5) use of any ocular 
medication within 14 days prior to study entry; 6) any ocular 
infection within month prior to study entry; 7) known or 
suspected allergy to ophthalmic preservatives, aminoglyco-
sides and steroids. Two hundred thirty-eight consecutive 
patients (116 males and 122 females) were screened and 
enrolled. Mean age was 72 years (range 42–90 years). Age 
and gender were well-matched among groups of treatment. 
Patients disposition, according to the CONSORT diagram, is 
displayed in Figure 1.
Interventions
Two hundred and thirty-eight patients were randomized, 
using a computer-generated list, in a 2:1 ratio to dexa/net 
(n=158) or beta/chl (n=80). The different packaging of two 
products did not allow a double-masked approach. 
Treatment started the day of surgery (day 0) administering 
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1 drop in the conjunctival sac of the operated eye and 
continued 4 times a day for 7±1 day. Afterwards investi-
gators could continue the anti-inflammatory treatment 
according to patient conditions and their clinical routine. 
Control visits were scheduled at day 1 and day 7 (±1) after 
surgery.
Outcomes
The examination at each visit included best corrected visual 
acuity, slit-lamp examination, ophthalmoscopy and applana-
tion tonometry. The primary efficacy parameter evaluated 
was the anterior chamber (AC) flare scored from none to 
severe using a 0 to 3-point scale (Table 1).15 Other 
Figure 1 Patients disposition.
Table 1 Scoring Systems Used in the Study
Score Anterior Chamber Flare Anterior 
Chamber 
Cells





0 none none none none none
1 mild (barely detectable) mild (1 to 10 
cells)
mild (some vessel injected) mild mild (present but not 
distressing)
2 moderate (iris and lens detail clear) moderate 
(11 to 50 
cells)
moderate (diffuse injection, 
individual vessels discernible)
moderate moderate (distressing but 
not interfering with daily 
life)
3 severe (iris and lens details not visible 
and fibrin in the anterior chamber)
severe (> 50 
cells)
severe (intense injection, 
individual vessels not easily 
discernible)
severe severe (very distressing and 
interfering with daily life)
Notes: Reproduced with permission from Papa V, Milazzo G, Santocono M, et al. Naproxen ophthalmic solution to manage inflammation after phacoemulsification. J Cataract 
Refract Surg. 2002;28(7):321–327. https://journals.lww.com/jcrs/Abstract/2002/02000/Naproxen_ophthalmic_solution_to_manage.39.aspx.15
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parameters of analysed included: AC cells, conjunctival 
hyperaemia, corneal and lid oedema, and symptoms of ocular 
discomfort (pain, burning, and tearing). All these clinical 
variables were also graded from none to severe using a 0 to 
3-point scale (Table 1).15 Safety variables monitored during 
the study were adverse events, intraocular pressure (IOP), 
and visual acuity.
Statistics
Statistical analysis was performed by an expert statistician 
using the SAS system version 9.2. The sample size esti-
mate was based on a one-sided test of equality of paired 
proportions of the primary end point. This was estimated 
to be 96% in the control group treated with dexamethasone 
for 10 days. Considering that in this trial treatment dura-
tion was 7±1 day, the estimated percentage of patients with 
AC flares was reduced to 90%. Based on this assumption, 
219 evaluable patients were required to detect at 15% 
difference between treatments to have a 90% chance 
(delta = 10%) of statistically proving efficacy, in a non- 
inferiority design study. To allow for about 10% subjects 
drop-out, a final sample size of 238 patients was planned. 
Statistical evaluation was performed as previously 
described for similar studies.8,15, Listing, tables, graphs, 
and statistical output were generated using the SAS soft-
ware. Briefly, the main efficacy parameter evaluated was 
AC flare at day 7 after surgery. The “efficacy rate” (pri-
mary efficacy parameter) was defined as the percentage of 
patients displaying none or mild AC flare (ie, score 0 or 1), 
whereas the “percentage of responders” (secondary effi-
cacy parameter) was defined as the percentage of patients 
showing a decrease of AC flare score from baseline and 
patients scoring 0 at both baseline and at Day 7 after 
surgery. Dexa/net would be declared effective, if it can 
be shown that the response rate is not inferior (by means 
of 97.5% confidence interval) to that of beta/chl. Statistical 
analyses were performed on predefined subsets. The Full 
Analysis Population (FA) consisted of subjects operated 
and treated for at least 5 days and that reached the end 
point visit (Day 7 after surgery). The Per-Protocol (PP) 
Population consisted of all subjects of the FA population 
without any relevant protocol deviations. The main effi-
cacy parameters (“efficacy rate” and “percent of respon-
ders”) were analysed in both FA and PP populations, 
whereas all other parameters were analysed in the FA 
population only. Safety was analysed in all subjects who 
received at least one dose of drug [Intention-to-Treat (ITT) 
population]. For other efficacy parameters, intraindividual 
score differences were calculated, assuming a zero differ-
ence if the respective post-dose values were not available. 
These score differences were compared between treat-
ments by the Mann–Whitney U-test or the Wilcoxon test 
for independent samples. All secondary efficacy para-
meters were presented by descriptive analysis. All safety 
results are presented with their descriptive analyses only. 
Adverse events (AEs) were coded using the MedDRA 
dictionary (version 14).
Results
As shown in Figure 1, the ITT population consisted of 238 
patients (dexa/net=158 and beta/chl=80). Seven patients 
were excluded due to a protocol violation and therefore 
the FA population consisted of 231 patients (dexa/net=153 
and beta/chl=78); the PP population included 190 patients 
fully adherent to the protocol (dexa/net=126 and beta/ 
chl=64). Patients were well-matched among groups 
regarding baseline characteristics.
Main efficacy results are displayed in Tables 2 and 3. 
After 7 days of treatment most of patients had no signs of 
inflammation in the anterior chamber. The main efficacy 
parameters (“efficacy rate” and “percentage of respon-
ders”) were comparable between groups. The p-value to 
reject the null hypothesis of inferiority was p<0.001 
(Table 2). Specifically, at the end point visit no AC flare 
Table 2 Primary Efficacy Outcomes
Dexa/Net Beta/Chl P values (Rejection of the Null Hypothesis) One Side 97.5% CI
Efficacy rate FA 100% 100% / /
PP 100% 100% / /
Responders FA 94.1% 93.6% <0.001 −0.061 +∞
PP 92.9% 92.2% 0.0002 −0.073 +∞
Notes: Efficacy rate= percentage of patients displaying at the study endpoint (day 7 after surgery) none or mild anterior chamber flare (ie, score 0–1). Responders= 
percentage of patients showing at the study endpoint (day 7 after surgery) a decrease of anterior chamber flare score from baseline or a score 0 at both visits (baseline 
and day 7). FA=full analysis population (dexa/net: n=153; beta/chl: n=78). PP= per-protocol population (dexa/net: n=126; beta/chl: n=64)
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was observed in 92.8% of patients treated with dexa/net 
and 92.3% of patients treated with beta/chl. In addition, no 
AC cell was detected in 92.8% of patients treated with 
dexa/net and 92.3% of patients treated with beta/chl 
(Table 3). Furthermore, all additional efficacy parameters 
evaluated (conjunctival hyperaemia, corneal oedema, and 
lid oedema) confirmed that both treatments were equally 
effective in reducing ocular inflammation (Table 3). Same 
conclusion can be draw also for ocular symptoms (tearing, 
burning and pain) (Table 4).
During the study, non-serious AEs occurred in 2.1% 
of patients (5/238). These AEs occurred in the group 
treated with dexa/net. Three events (subconjunctival 
hemorrhage, retinal hemorrhage, and capsular rupture) 
were considered not related to treatment but to the 
surgical procedure, whereas two cases of allergic con-
junctivitis were considered related to the use of dexa/ 
net. Final IOP was 14.3±2.3 mmHg (mean ±SD) in the 
group treated with dexa/net and 14.1±2.3 mmHg in the 
group treated with beta/chl. Final visual acuity was 8.7 
±2.0 decimals (mean ±SD) in the dexa/net group vs 8.9 
±1.7 in the beta/chl group.
Discussion
Cataract surgery is the most common surgical intervention. 
Despite actual techniques have reduced considerably signs 
Table 3 Additional Efficacy Outcomes








Dexa/Net Beta/Chl Dexa/Net Beta/Chl Dexa/Net Beta/Chl
Full Analysis Population, N 153 78 153 78
N (%) N (%) N (%) N (%)
Anterior chamber flare score 0.385 <0.0001 <0.0001
0=None 53 (34.7%) 34 (43.6%) 142 (92.8%) 72 (92.3%)
1=Mild 92 (60.1%) 38 (48.7%) 11 (7.2%) 6 (7.7%)
2=Moderate 8 (5.2%) 6 (7.7%) 0 0
3=Severe 0 0 0 0
Anterior chamber cells score 0.941 <0.0001 0.0499
0=None, 85 (55.6%) 47 (60.3%) 140 (91.5%) 73 (93.5%)
1=Mild 57 (37.2%) 22 (28.2%) 13 (8.5%) 5 (6.5%)
2=Moderate 11 (7.2%) 9 (11.5%) 0 0
3=Severe 0 0 0 0
Conjunctival hyperaemia 0.4594 <0.0001 <0.0001
0= None 75 (49.0%) 38 (48.8%) 126 (83.3%) 70 (89.7%)
1=Mild 69 (45.1%) 36 (46.1%) 22 (14.4%) 8 (10.3%)
2=Moderate 9 (5.9%) 4 (5.1%) 4 (2.6%) 0
3=Severe 0 0 1 (0.6%) 0
Lid oedema 0.128 <0.0001 0.0499
0=None 125 (81.7) 70 (89.7) 150 (98.0) 76 (97.4)
1=Mild 28 (18.3) 7 (8.9) 2 (1.3) 2 (2.5)
2=Moderate 0 1 (1.2) 1 (0.6) 0
3=Severe 0 0 0 0
Corneal oedema 0.852 <0.0001 0.0499
0=None 60 (39.2%) 31 (39.7%) 148 (96.7%) 75 (96.1%)
1=Mild 70 (45.7%) 32 (41.1%) 5 (3.3%) 3 (3.9%)
2=Moderate 20 (13.1%) 14 (17.9%) 0 0
3=Severe 3 (2.0%) 1 (1.3%) 0 0
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of post-surgical inflammation and the risk of endophthal-
mitis, patients are often treated in the post-operative period 
with topical steroids and antibiotics (frequently in a fixed 
combination) as well as with non-steroidal anti- 
inflammatory drugs.2–7
The aim of this study was to evaluate the effectiveness 
of a short treatment with a steroid/antibiotic fixed combi-
nation containing 1 mg/mL dexamethasone and 3 mg/mL 
netilmicin in the control of post-operative inflammation. 
Results have shown that after 7 days more that 90% of 
patients have no sign of inflammation in the anterior 
chamber (AC flare and AC cells = score 0) and that the 
others have only a negligible level of inflammation 
(score 1). Accordingly, also signs of ocular surface inflam-
mation were absent (score 0) at the study endpoint (7 days) 
in most patients (82% for conjunctival hyperaemia, 97% 
for corneal oedema and 98% lid oedema). The control 
treatment used in the study was another steroid-antibiotic 
fixed combination containing 2 mg/mL betamethasone and 
5 mg/mL chloramphenicol. It is interesting to note that 
both treatments had a comparable anti-inflammatory effi-
cacy rate despite the double dose of steroid present in beta/ 
chl. This finding suggests, therefore, that a short-term 
treatment with 1 mg/mL dexamethasone is appropriate to 
manage post-surgical inflammation and that a stronger and 
extended exposure to steroids is not necessary. This 
ensures an effective control of post-operative inflammation 
and, at the same time, reduces the risk of developing 
corticosteroid-related side effects and avoids an overuse 
of antibiotics.
In our opinion, the main benefit of dexa/net over other 
available steroid-antibiotic fixed combinations is related to 
the antibiotic component. Indeed, netilmicin has a wide- 
spectrum activity (which also includes methicillin-resistant 
strains)12–14 and a negligible toxicity for the ocular surface.16 
Since post-surgical infections are due to microorganisms 
resident in the ocular surface, mainly Coagulase-negative 
Staphylococci (in particular S. epidermidis) and 
S. Aureus,17 it is critical to use antibiotics highly effective 
on these germs. If not eradicated, these bacteria may enter 
inside the eye starting the day of surgical procedure until 
corneal incision is fully closed. For this reason, antibiotic 
treatment, when used, should starts the same day of surgery. 
Netilmicin is able to sterilize lid margins and conjunctiva 
when given before cataract surgery.14,18 Moreover, the bac-
terial flora on the ocular surface isolated from patients 
Table 4 Ocular Symptoms








Dexa/Net Beta/Chl Dexa/Net Beta/Chl Dexa/net Beta/chl
Full Analysis Population, N 153 78 153 78
N (%) N (%) N (%) N (%)
Tearing 0.402 0.0030 0.0029
0=None 119 (77.8%) 55 (70.5%) 135 (88.2%) 68 (87.1%)
1=Mild 32 (20.9%) 22 (28.2%) 16 (10.5%) 10 (12.8%)
2=Moderate 2 (1.3%) 1 (1.3%) 2 (1.3%) 0
3=Severe 0 0 0 0
Burning 0.652 <0.0001 0.0030
0=None, 117 (74.0%) 64 (82.1%) 140 (91.5%) 73 (93.5%)
1=Mild 38 (24.1%) 15 (19.2%) 13 (8.5%) 5 (6.5%)
2=Moderate 3 (1.9%) 1 (1.3%) 0 0
3=Severe 0 0 0 0
Pain 0.032 0.070 0.0007
0= None 137 (89.5%) 63 (80.8%) 145 (94.8%) 77 (98.7%)
1=Mild 16 (10.5%) 13 (16.7%) 7 (4.6%) 0
2=Moderate 0 2 (2.5%) 0 1 (1.3%)
3=Severe 0 0 1 (0.6%) 0
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undergoing cataract surgery is highly susceptible to netilmi-
cin and much less to other antibiotics.14 It is important to 
highlight that, regardless their source, S.Aureus and 
Coagulase-negative Staphylococci isolates are often charac-
terized by methicillin resistance (MR) and multiresistance 
(MDR) to several classes of antibiotics; this finding is even 
more common in older patients, as those operated for 
cataract.19 Netilmicin is effective on methicillin-resistant 
S. Aureus (MRSA), methicillin-resistant Coagulase- 
negative Staphylococci (MRCoNS) and MDR Coagulase- 
negative Staphylococci,12–14 whereas these microorganisms 
display a high resistance to fluoroquinolones.12,13,19
As a potential limitation of the study, AC inflammation 
was measured, for practical reasons, by slit-lamp examina-
tion rather than by a laser flare and cell meter. Even if the 
scoring system used to measure flare and cells by slit-lamp 
examination is subjective and semi-quantitative, yet it cor-
responds to the actual daily routine of practice. Moreover, 
a consistency of results obtained with bio-microscopy and 
laser flare and cells meter measurements has been 
described.20 In summary, a short-term use of dexa/net 
fixed combination is effective as beta/chl in the control of 
post-operative inflammation following uncomplicated cat-
aract surgery.
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